In addition, the antibody ramucirumab targeting VEFGR‐2 has shown promising results in clinical trials.[39, 40, 41, 42] However, agents targeting EGFR, mTOR, or VEGF‐A have not shown any definite survival benefit in patients with GC.[5] Given that research into the molecular biology of tumors is rapidly advancing, targeted molecular therapy can significantly benefit patients with cancer. Here, EGFR is linked to gastric cancer.